Based on the Natera Inc stock forecast from 13 analysts, the average analyst target price for Natera Inc is USD 155.64 over the next 12 months. Natera Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Natera Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Natera Inc’s stock price was USD 161.88. Natera Inc’s stock price has changed by -2.80% over the past week, -4.42% over the past month and +168.50% over the last year.
No recent analyst target price found for Natera Inc
No recent average analyst rating found for Natera Inc
Company Overview Natera Inc
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. Read Less
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test...Read More
Frequently Asked Questions About Natera Inc (NTRA) Stock
Based on ratings from 13 analysts Natera Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 22 buy, sell and hold ratings.
Unfortunately we do not have enough data on NTRA's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for NTRA is USD 155.64 over the next 12 months. The maximum analyst target price is USD 200 while the minimum anlayst target price is USD 120.
Unfortunately we do not have enough data on NTRA's stock to indicate if its overvalued.
The last closing price of NTRA's stock was USD 161.88.
The most recent market capitalization for NTRA is USD 22.06B.
Based on targets from 13 analysts, the average taret price for NTRA is projected at USD 155.64 over the next 12 months.
This means that NTRA's stock price may go down by -3.86% over the next 12 months.
We can't find any ETFs which contains Natera Inc's stock.
As per our most recent records Natera Inc has 3,282 Employees.
Natera Inc's registered address is 13011 McCallen Pass, Austin, TX, United States, 78753.
You can get more information about it from Natera Inc's website at https://www.natera.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Natera Inc (NTRA) Stock
Based on ratings from 13 analysts Natera Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 22 buy, sell and hold ratings.
Unfortunately we do not have enough data on NTRA's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for NTRA is USD 155.64 over the next 12 months. The maximum analyst target price is USD 200 while the minimum anlayst target price is USD 120.
Unfortunately we do not have enough data on NTRA's stock to indicate if its overvalued.
The last closing price of NTRA's stock was USD 161.88.
The most recent market capitalization for NTRA is USD 22.06B.
Based on targets from 13 analysts, the average taret price for NTRA is projected at USD 155.64 over the next 12 months.
This means that NTRA's stock price may go down by -3.86% over the next 12 months.
We can't find any ETFs which contains Natera Inc's stock.
As per our most recent records Natera Inc has 3,282 Employees.
Natera Inc's registered address is 13011 McCallen Pass, Austin, TX, United States, 78753.
You can get more information about it from Natera Inc's website at https://www.natera.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NTRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
